Ozonation of a Municipal Surface Water Supply to Reduce Trihalomethane Formation and the Use of Surrogate Parameters to Predict Trihalomethane Concentrations

Numerous researchers have shown that THMs are essentially absent in natural waters but are nearly always present in chlorinated water supplies. Furthermore, it is generally agreed that THMs are formed by the reaction of chlorine with organic precursors, particularly humic substances, in the water. Thus, since surface waters typically are higher in organics, surface water supplies are usually higher in halogenated organics. The factors controlling production of THMs during potable water treatment have been investigated for a number of water supplies. Water parameters such as temperature, total organic carbon (TOC) content, pH, color, chlorine demand, turbidity, and water type (surface water or groundwater) have been shown to affect THM production. Because the analysis for THMs is a time-consuming and relatively expensive gas chromatographic procedure, a simple, rapid surrogate measurement that. would predict THM concentration with reasonable accuracy would seem desirable. Chlorine reacts with organic precursors in the water to form THMs, therefore a test that would measure these precursor concentrations in the raw water would be useful for anticipating finished water THMs. Through the use of these measurements, parameters influencing THM production most could be identified. If a suitable surrogate parameter could be found, it would be useful in routine water quality monitoring process control even though it may be of insufficient accuracy for evaluating compliance with EPA guidelines. The City of Yankton, South Dakota, draws its drinking water supply from the Missouri River. The raw water contains organic matter which may cause THMs upon chlorination, tastes, odors, increased chlorine demand, and reduced flocculation efficiency. Investigations were conducted to determine the abi1ity of ozone to reduce the formation of trihalomethanes. Raw water and raw water samples ozonated at contact times of 5, 10 and 15 minutes were chlorinated and analyzed for THMs at various times after chlorination. Jar tests were also used to determine the effect of coagulation on THM formation for both raw and ozonated raw water. Following chemical additions, stirring, and settling, the water samples were chlorinated and after various reaction times, the THM concentration was determined. Another objective involved the evaluation of ozone pilot plant data to seek out passib1e surrogate parameters for THMs. Data for both Yankton and Huron and were used for this investigation. The various parameters investigated were chemical oxygen demand (COD), true color, apparent color, raw ultraviolet (UV) absorbance, filtered UV absorbance, and TOC

Mapping Wind Direction with HF Radar

The article of record as published may be found at https://www.jstor.org/stable/43924806Office of Naval ResearchH.C. Graber acknowledges the sup- port by the Office of Naval Research through grant N00014-94-1-1016 (DUCK94)

Lamellar body ultrastructure revisited: high-pressure freezing and cryo-electron microscopy of vitreous sections

Lamellar bodies are the storage sites for lung surfactant within type II alveolar epithelial cells. The structure-function models of lamellar bodies are based on microscopic analyses of chemically fixed tissue. Despite available alternative fixation methods that are less prone to artifacts, such as cryofixation by high-pressure freezing, the nature of the lung, being mostly air filled, makes it difficult to take advantage of these improved methods. In this paper, we propose a new approach and show for the first time the ultrastructure of intracellular lamellar bodies based on cryo-electron microscopy of vitreous sections in the range of nanometer resolution. Thus, unspoiled by chemical fixation, dehydration and contrasting agents, a close to native structure is revealed. Our approach uses perfluorocarbon to substitute the air in the alveoli. Lung tissue was subsequently high-pressure frozen, cryosectioned and observed in a cryo-electron microscope. The lamellar bodies clearly show a tight lamellar morphology. The periodicity of these lamellae was 7.3nm. Lamellar bifurcations were observed in our cryosections. The technical approach described in this paper allows the examination of the native cellular ultrastructure of the surfactant system under near in vivo conditions, and therefore opens up prospectives for scrutinizing various theories of lamellar body biogenesis, exocytosis and recyclin

The effects of introducing sterically demanding aryl substituents in [Cu(N^N)(P^P)]+ complexes

The syntheses and characterizations of six [Cu(N^N)(POP)][PF 6 ] and [Cu(N^N)(xantphos)][PF 6 ] compounds (POP = bis(2-(diphenylphosphino)phenyl)ether, xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene), in which N^N is a bpy ligand (1-Naphbpy, 2-Naphbpy, 1-Pyrbpy) bearing a sterically hindered 1-naphthyl, 2-naphthyl or 1-pyrenyl substituent in the 6-position, are reported. Single-crystal structure determinations of five complexes confirm a distorted tetrahedral environment for copper( I ) and a preference for the N^N ligand to be oriented with the sterically-demanding aryl group being remote from the (C 6 H 4 ) 2 O unit of POP or the xanthene ‘bowl’ of xantphos. The angle between the ring planes of the bpy range from 5.8 to 26.0° and this is associated with interactions between the aryl unit and the phenyl substituents of the P^P ligand. In solution at room temperature, the complexes undergo dynamic behaviour which has been investigated using variable temperature 2D NMR spectroscopy. The [Cu(N^N)(xantphos)] + complexes exist as a mixture of conformers which interconvert through inversion of the xanthene bowl-shaped unit; the preference for one conformer over the other is significantly changed on going from N^N = Phbpy to 1-Pyrbpy (Phbpy = 6-phenyl-2,2’-bipyridine). The electrochemical and photophysical properties of the [Cu(N^N)(POP)][PF 6 ] and [Cu(N^N)(xantphos)][PF 6 ] compounds are presented; the compounds are orange emitters but the introduction of the 1-naphthyl, 2-naphthyl or 1-pyrenyl substituents result in poor photoluminescence quantum yields

Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model

The airways of patients with cystic fibrosis are colonized with diverse bacterial communities that change dynamically during pediatric years and early adulthood. Staphylococcus aureus is the most prevalent pathogen during early childhood, but during late teens and early adulthood, a shift in microbial composition occurs leading to Pseudomonas aeruginosa community predominance in ∼50% of adults. We developed a robust dual-bacterial in vitro coculture system of P. aeruginosa and S. aureus on monolayers of human bronchial epithelial cells homozygous for the ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) mutation to better model the mechanisms of this interaction. We show that P. aeruginosa drives the S. aureus expression profile from that of aerobic respiration to fermentation. This shift is dependent on the production of both 2-heptyl-4-hydroxyquinoline N-oxide (HQNO) and siderophores by P. aeruginosa. Furthermore, S. aureus-produced lactate is a carbon source that P. aeruginosa preferentially consumes over medium-supplied glucose. We find that initially S. aureus and P. aeruginosa coexist; however, over extended coculture P. aeruginosa reduces S. aureus viability, also in an HQNO- and P. aeruginosa siderophore-dependent manner. Interestingly, S. aureus small-colony-variant (SCV) genetic mutant strains, which have defects in their electron transport chain, experience reduced killing by P. aeruginosa compared to their wild-type parent strains; thus, SCVs may provide a mechanism for persistence of S. aureus in the presence of P. aeruginosa. We propose that the mechanism of P. aeruginosa-mediated killing of S. aureus is multifactorial, requiring HQNO and P. aeruginosa siderophores as well as additional genetic, environmental, and nutritional factors

Structural plasticity of spines at giant mossy fiber synapses

The granule cells of the dentate gyrus give rise to thin unmyelinated axons, the mossy fibers. They form giant presynaptic boutons impinging on large complex spines on the proximal dendritic portions of hilar mossy cells and CA3 pyramidal neurons. While these anatomical characteristics have been known for some time, it remained unclear whether functional changes at mossy fiber synapses such as long-term potentiation (LTP) are associated with structural changes. Since subtle structural changes may escape a fine-structural analysis when the tissue is fixed by using aldehydes and is dehydrated in ethanol, rapid high-pressure freezing (HPF) of the tissue was applied. Slice cultures of hippocampus were prepared and incubated in vitro for 2 weeks. Then, chemical LTP (cLTP) was induced by the application of 25 mM tetraethylammonium (TEA) for 10 min. Whole-cell patch-clamp recordings from CA3 pyramidal neurons revealed a highly significant potentiation of mossy fiber synapses when compared to control conditions before the application of TEA. Next, the slice cultures were subjected to HPF, cryosubstitution, and embedding in Epon for a fine-structural analysis. When compared to control tissue, we noticed a significant decrease of synaptic vesicles in mossy fiber boutons and a concomitant increase in the length of the presynaptic membrane. On the postsynaptic side, we observed the formation of small, finger-like protrusions, emanating from the large complex spines. These short protrusions gave rise to active zones that were shorter than those normally found on the thorny excrescences. However, the total number of active zones was significantly increased. Of note, none of these cLTP-induced structural changes was observed in slice cultures from Munc13-1 deficient mouse mutants showing severely impaired vesicle priming and docking. In conclusion, application of HPF allowed us to monitor cLTP-induced structural reorganization of mossy fiber synapses

Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy-A Registry-Based Cohort Study.

Atypical femoral fractures (AFFs) have been reported in patients taking bisphosphonates (BPs) for osteoporosis therapy but also in patients with no exposure to these drugs. In contrast, less is known about the incidence of AFFs in patients taking denosumab. This registry-based cohort study analyzed the incidence of AFFs in patients with suspected or confirmed osteoporosis who were included in the osteoporosis register of the Swiss Society of Rheumatology between January 2015 and September 2019. Statistical analyses included incidence rates, rate ratios, and hazard ratios for AFFs, and considered sequential therapies and drug holidays as time-dependent covariates. Among the 9956 subjects in the cohort, 53 had subtrochanteric or femoral shaft fractures. Ten fractures occurred under BP or denosumab treatment and two under teriparatide therapy. Five fractures were classified as AFFs based on the revised American Society of Bone and Mineral Research case definition of AFFs from 2014. Three AFFs occurred in women being treated with denosumab at the time of diagnosis, all with prior BP use (10, 7, and 1 years, respectively). One AFF developed in a woman receiving ibandronate and one arose in a woman receiving glucocorticoids rather than antiresorptive therapy. The incidence of AFFs per 10,000 observed patient-years was 7.1 in patients receiving denosumab and 0.9 in patients with BP-associated AFFs, yielding a rate ratio of 7.9 (95% confidence interval [CI] 0.63-413), p = 0.073. The risk of AFFs was not significantly higher in patients receiving denosumab therapy compared with BP therapy (hazard ratio = 7.07, 95% CI 0.74-68.01, p = 0.090). We conclude that the risk of AFFs is low in patients taking BPs, denosumab, or both sequentially. All three patients with AFFs under denosumab therapy had undergone prior BP therapy. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research

Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.

UNLABELLED This registry-based study of 3068 patients with osteoporosis compared the anti-fracture effectiveness of denosumab versus bisphosphonates. Denosumab was associated with significantly greater risk reduction than alendronate or ibandronate for vertebral and any fractures. No difference in fracture risk reduction was found between zoledronate and denosumab. PURPOSE To analyse the fracture risk of patients with osteoporosis receiving bisphosphonates or denosumab in a real-world setting. METHODS This registry-based cohort study evaluated patients taking denosumab, bisphosphonates or both sequentially. Fractures were analysed using rates, rate ratios and hazard ratios (HR), including both therapies as time-varying co-variates. Fracture risk hazards were adjusted (aHR) for baseline T-Scores and trabecular bone score (TBS) and were additionally analysed with inverse probability treatment weighting. RESULTS A total of 3068 patients (89% female; median age at treatment onset, 69 years [63 to 76]) received denosumab (median duration 2.8 years, [2.2 to 4.7]), bisphosphonates (3.4 years, [2.1 to 5.7]) or both sequentially. Thus, 11,078 subject-years were assessed for bisphosphonates (41% alendronate, 36% ibandronate, 23% zoledronate) and 4216 for denosumab. Moreover, 48,375 subject-years were observed before treatment onset, in addition to 2593 years of drug holidays. A total of 1481 vertebral fractures (435 under therapy), 1508 non-vertebral fractures (499 under therapy) and 202 hip fractures (67 under therapy) occurred after age 50. The risks of vertebral, non-vertebral and hip fractures were significantly lower under all bisphosphonates, denosumab and drug holidays than before treatment onset (all p < 0.001). After adjusting for age, baseline T-scores and TBS, denosumab was associated with lower risk than alendronate or ibandronate for vertebral fractures (aHR 0.47 (0.35 to 0.64) and 0.70 [0.53 to 0.91], p < 0.001 and p = 0.009, respectively) and any fractures (aHR 0.62 [0.51 to 0.76] and 0.77 [0.64 to 0.92], p < 0.001 and p = 0.004). With propensity weighting, denosumab was associated with a lower hip fracture risk compared to alendronate (HR 0.54 [0.29 to 0.98], p = 0.044). No difference in fracture risk reduction (vertebral, non-vertebral or hip) was found between zoledronate and denosumab. CONCLUSIONS When adjusting for disease severity, denosumab was associated with significantly greater risk reduction than alendronate and ibandronate for vertebral fractures. No difference in fracture risk reduction was found between zoledronate and denosumab